An Effective Nanoparticle-Biomaterial in Alleviating Diabetic Cataracts

Abstract

To test an effective nanoparticle-biomaterial in alleviating diabetic cataracts (DC), CCTSOS. Composed mainly of CeCl3 and TiSiO4, nanoparticle-biomaterial was invented as an new compound nano-drug for DC treatment in these researches. To prove its anti-DC capacity, antioxidation and antiglycation in vitro and in vivo were tested and macroscopic and microscopic studies on cataract progression were carried out. hLECs and α-crystallin were used for extracorporeal test on antioxidation and antiglycation and STZ-induced mouse model was used for anti-DC test in vivo. The results showed that CCTSOS can inhibit oxidation by reducing superoxides and peroxides. While there was an increase of SOD and PRDX1 in hLECs, there was also a decrease of MDA and an increase of GSH in vivo. CCTSOS can alleviate glycation as shown in the decrease of CEL and the flourescence intensity of final glycated α-crystallin in vitro and in vivo. In terms of DC rescue, CCTSOS could slow down DC progress as shown in macroscopic image and grading score and presented in LECs smear and eye slice. In conclusion, CCTSOS has a significant effect of antioxidation and antiglycation and an anti-DC effect both in vitro and in mouse model, implying that CCTSOS can be a potentially compound nano-drug for DC treatment in the future.